gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · CSTLHealthcareMedical Labs

Castle Biosciences, Inc. Common Stock (CSTL)

$35.75+1.74%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$35.14▲ 35.21% in range
Nov 3, 2025Low $18.15 · High $43.04Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Castle Biosciences closed at $35.75 on Nov 4, up 1.74%, 16.9% below its 52-week closing high. Volume of 462.7K shares was 1.34× its 20-day average (above normal).

Split-adjusted performance: +7.2% over one month, +44.4% over six months, +37.6% over one year.

In the quarter ended Jun 30, 2026, revenue was $103.55M, up 20.1% from a year earlier, with a net margin of -2.0%.

Short interest was 2.0M shares at the Oct 15 settlement (7.1% of float, 6.0 days to cover).

Market cap$1.09B30.5M shares
Revenue · quarter$103.5M+20.1% YoY
Diluted EPS$-0.07−146.7% YoY
P/E · TTM—P/S 3.1×
Net margin-2.0%Gross 77.1%
Dividend yieldNone
52-week range18.15 – 43.04−16.9% from high
Volume462.7K1.34× 20-day avg
Volatility · 60d51.9%Annualised
Short % of float7.1%6.0 days to cover
Net cash$256.5MCash $266.8M
Next earnings—Not scheduled
Split-adjusted performance
1W −2.5%1M +7.2%3M +17.3%6M +44.4%YTD −8.1%1Y +37.6%3Y +151.2%5Y −41.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Medical Labs

Percentile among 24 companies (100 = best)

6-month momentum68
Revenue growth44
Net margin52
Value (low P/E)—
Size35

Industry medians: 6-month return +36.9%, revenue growth +25.0%, net margin −4.0%, P/E 32.4×.

Short interest

Details →
Shares short2.0M+0.8% vs prior
Days to cover6.0Settled Oct 15
% of float7.1%
Short vol. 10d43.8%of daily volume

Closest peers by size in Medical Labs

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
CSTLCastle Biosciences$35.75+1.74%+44.4%+20.1%−2.0%—$1.09B
FRNMFreenome$11.30−1.48%————$1.21BCompare
LMRILumexa Imaging Holdings$13.10+16.76%+27.4%—1.0%—$1.26BCompare
PSNLPersonalis$15.79+0.25%+160.1%+30.0%−141.7%—$1.69BCompare
FTREFortrea Holdings$20.83−0.57%+33.2%−1.4%0.1%—$2.01BCompare
FLGTFulgent Genetics$19.68+1.60%+31.9%+4.4%−34.6%—$541.5MCompare
CELCCelcuity$69.24−0.69%−50.3%———$3.39BCompare
VCYTVeracyte$52.52+4.43%+27.5%+15.5%17.0%36.9$4.22BCompare
CDNACareDx$85.86−2.95%+309.8%+39.3%13.8%35.1$4.51BCompare

News about Castle Biosciences

All news →
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% RiskGlobeNewswire Inc. · Mar 9, 2026▲ Positive

Quick answers

What does Castle Biosciences do?
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma.
What is CSTL's market cap?
$1.09B, based on the Nov 4 close of $35.75.
Does Castle Biosciences pay a dividend?
No regular cash dividend has been paid in the last year.
How much of CSTL is sold short?
2.0M shares, 7.1% of float, as of Oct 15, 2026.
What sector is CSTL in?
Healthcare, in the Medical Labs industry.

About Castle Biosciences

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

HQ: Friendswood, TX1,002 employeesListed Jul 25, 2019castlebiosciences.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology